79633-18-4|净司他丁|Zinostatin|-范德生物科技公司

净司他丁

NMR下载 COA and HPLC MSDS下载
names：
Zinostatin
CAS号：
79633-18-4
MDL Number：
MF(分子式)： C35H35NO12 MW(分子量)： 661.66
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	净司他丁; 新制癌菌素
英文别名	Zinostatin; Neocarcinostatin
CAS号	79633-18-4
SMILES	CC1=CC(OC)=CC2=C1C=CC(O)=C2C(O[C@@H]3C=C4C#C[C@@]5(C6COC(O6)=O)C(C#CCC4[C@H]3O[C@@H]7[C@H](NC)[C@@H](O)[C@@H](O)[C@@H](C)O7)O5)=O
Inchi	InChI=1S/C35H35NO12/c1-16-12-19(42-4)14-22-20(16)8-9-23(37)27(22)32(40)45-24-13-18-10-11-35(26-15-43-34(41)46-26)25(48-35)7-5-6-21(18)31(24)47-33-28(36-3)30(39)29(38)17(2)44-33/h8-9,12-14,17,21,24-26,28-31,33,36-39H,6,15H2,1-4H3/t17-,21?,24-,25?,26?,28-,29+,30-,31-,33-,35+/m1/s1
InchiKey	BLXZMHNVKCEIJX-LTZUVELHSA-N
分子式 Formula	C35H35NO12
分子量 Molecular Weight	661.66
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Zinostatin(CAS:2598369):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Zinostatin is a cytotoxic enediyne that alkylates DNA and RNA like mitomycin does. It has antineoplastic and antibiotic properties. It is isolated from the bacterium Streptomyces carzinostaticus. It may be active against hepatocellular carcinoma.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Nichols JW, Bae YH. EPR: Evidence and fallacy. J Control Release. 2014 Sep 28;190:451-64. doi: 10.1016/j.jconrel.2014.03.057. Epub 2014 Apr 30. Review. PubMed PMID: 24794900.

[2]Ishii H, Furuse J, Nagase M, Maru Y, Yoshino M, Hayashi T. A phase I study of hepatic arterial infusion chemotherapy with zinostatin stimalamer alone for hepatocellular carcinoma. Jpn J Clin Oncol. 2003 Nov;33(11):570-3. PubMed PMID: 14711981.

[3] Okusaka T, Okada S, Ueno H, Ikeda M, Iwata R, Furukawa H, Takayasu K, Moriyama N, Sato T, Sato K. Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology. 2002;62(3):228-33. PubMed PMID: 12065870.

[4] Toge T, Jinushi K, Sawamura A, Matsuki K. [Study on the intra-tumor tissue concentration of zinostatin stimalamer in the liver following intra-arterial injection of zinostatin stimalamer (YM881) suspension]. Gan To Kagaku Ryoho. 1991 Aug;18(10):1677-80. Japanese. PubMed PMID: 1651687.

[5] Sansiaume-Dagousset E, Urvoas A, Chelly K, Ghattas W, Maréchal JD, Mahy JP, Ricoux R. Neocarzinostatin-based hybrid biocatalysts for oxidation reactions. Dalton Trans. 2014 Jun 14;43(22):8344-54. doi: 10.1039/c4dt00151f. PubMed PMID: 24728274.

6: Hirashima N, Sakakibara K, Itazu I, Hirai T, Nemoto A, Matsuura H, Kumada K, Nojiri O, Kano H. Zinostatin stimalamer-transcatheter arterial embolization for hepatocellular carcinoma: a comparison with lipiodol-transcatheter arterial embolization. Semin Oncol. 1997 Apr;24(2 Suppl 6):S6-91-S6-96. PubMed PMID: 9151922.7: Urvoas A, Ghattas W, Maréchal JD, Avenier F, Bellande F, Mao W, Ricoux R, Mahy JP. Neocarzinostatin-based hybrid biocatalysts with a RNase like activity. Bioorg Med Chem. 2014 Oct 15;22(20):5678-86. doi: 10.1016/j.bmc.2014.05.063. Epub 2014 Jun 14. PubMed PMID: 24984934.8: Fukuhara K, Suzuki M, Unno M, Rikiyama T, Sakamoto N, Takeuchi H, Uchiyama T, Yamaki T, Iwasashi H, Kodama H, Matsuno S. [An anaphylactic shock case after hepatic arterial infusion of zinostatin stimalamer suspension improved by anti-histaminics]. Gan To Kagaku Ryoho. 1997 Jun;24(8):1023-6. Japanese. PubMed PMID: 9212813.9: Tianqin G, Chunlei C, Jingjing W. Synergistic Anti-glioma Effects in Vitro and in Vivo of Enediyne Antibiotic Neocarzinostatin and Paclitaxel via Enhanced Growth Delay and Apoptosis-Induction. Biol Pharm Bull. 2016 Oct 1;39(10):1623-1630. Epub 2016 Jul 14. PubMed PMID: 27431785.10: Issell BF, Ginsberg SJ, Comis RL. Zinostatin and doxorubicin. A combination phase I study. Cancer Clin Trials. 1981 Fall;4(3):323-6. PubMed PMID: 6269771.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开